An efficient method for analyzing seven sexual hormones (estradiol-17beta, estriol, estrone, testosterone, methyl-testosterone, progesterone and diethylstilbestrol) in essential oil by high performance liquid chromatography was developed. The samples were dissolved in n-hexane, then extracted with 90% methanol solution. The n-hexane layer was discarded and the methanol layer was cleaned-up twice with n-hexane. The target compounds were separated on an XTerra RP18 column (250 mm x 4.6 mm, 5 microm) using water-methanol-acetonitrile (50:30:20, v/v/v) as mobile phase in isocratic mode, and detected by a diode array detector (DAD) and a fluorescence detector (FLD). The flow rate was 1.0 mL/min. Estriol, estradiol-17beta, estrone, diethylstilbestrol were detected at 197 nm; progesterone, testosterone, methyl-testosterone were detected at 240 nm; estriol, estradiol-17beta, estrone were detected with the fluorescence detector simultaneously, the excitation and emission wavelengths were 280 nm and 310 nm, respectively. The average spiked recoveries for seven sexual hormones were above 93.0% except that of progesterone was 79.5%. The relative standard deviations of seven sexual hormones were from 0.90% to 1.89%. The linear ranges of the determination were from 0.010 mg/L to 1.0 mg/L. The method is simple and accurate for simultaneously analyzing the seven sexual hormones in essential oil.
Download full-text PDF |
Source |
---|
Eur Urol Open Sci
December 2024
Martini-Klinik Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background And Objective: In patients with oligorecurrent prostate cancer (PCa), prostate-specific membrane antigen-targeted radioguided surgery (PSMA-RGS) prolongs treatment-free survival. Data on patient-reported outcome measures (PROMs) are lacking.
Methods: A retrospective assessment of validated PROMs (12-item Short Form Health Survey [SF-12], 26-item Expanded Prostate Index Composite, and Decision Regret Scale [DRS]) was performed before and after PSMA-RGS for oligorecurrent PCa.
Acta Physiol (Oxf)
February 2025
Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
The blood-brain barrier (BBB) is a highly selective, semipermeable barrier critical for maintaining brain homeostasis. The BBB regulates the transport of essential nutrients, hormones, and signaling molecules between the bloodstream and the central nervous system (CNS), while simultaneously protecting the brain from potentially harmful substances and pathogens. This selective permeability ensures that the brain is nourished and shielded from toxins.
View Article and Find Full Text PDFClin Transl Oncol
January 2025
Department of Medical Oncology, University Hospital of Navarra, Instituto de Investigación Sanitaria de Navarra, IdISNA, Navarra, Spain.
Males have a higher incidence and mortality rate from colorectal cancer (CRC) compared with females. This review examines the reasons for these differences, including risk factors, screening participation, interpretation of screening tests, presentation and tumour types, pathophysiology (particularly the impact of sex hormones on tumour-related gene expression, microsatellite instability, micro-RNA expression, and the tumour microenvironment), and the efficacy and toxicity of treatment. Sex differences in hormones and body composition are responsible for some of the sexual dimorphism in CRC incidence and outcomes, particularly the pathophysiology, CRC presentation, the pharmacokinetics of cytotoxic therapies, and the impact of treatment on outcomes.
View Article and Find Full Text PDFClimacteric
January 2025
Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Testosterone is unquestionably a normal female hormone that exerts important physiological effects in multiple tissues. Clinical trials have consistently demonstrated benefits of testosterone therapy on several domains of sexual function for postmenopausal women with low sexual desire causing substantial personal concern. Whether other benefits can be attributed to testosterone therapy for postmenopausal women remains uncertain.
View Article and Find Full Text PDFMaturitas
January 2025
Theramex, London, UK. Electronic address:
Introduction: Despite research supporting menopause hormonal therapy for menopausal women, its use continues to decline in most European countries and the United States. Experts highlighted the need for global assessment tools to assist clinicians in evaluating treatment for symptomatic menopausal women, which led to the development of the Menopause Treatment Tool, with separate versions for women and healthcare professionals. Both versions of the tool focus on menopausal symptoms, risk levels and suggested actions; the women's tool is administered prior to the consultation, while the clinician tool is administered by the clinician during the clinical consultation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!